Neuroscience 2002 Abstract
| Presentation Number: | 519.8 |
|---|---|
| Abstract Title: | CHARACTERISATION OF THE EFFECTS OF THE DOPAMINE D<sub>2/3</sub> RECEPTOR AGONIST QUINELORANE IN RATS USING FUNCTIONAL MAGNETIC RESONANCE IMAGING.<sub></sub> |
| Authors: |
Ireland, M. D.*1
; Lowe, A. S.1
; James, M. F.2
; Leslie, R. A.2
; Williams, S. C. R.1
1Neuroimaging Res Group, Inst Psychiatry, London, United Kingdom 2GlaxoSmithKline Pharmaceuticals, England, United Kingdom |
| Primary Theme and Topics |
Techniques in Neuroscience - Staining, tracing and imaging techniques |
| Secondary Theme and Topics | Motor Systems<br />- Basal Ganglia<br />-- Transmitters and receptors |
| Session: |
519. Staining, tracing, and imaging techniques VI Slide |
| Presentation Time: | Tuesday, November 5, 2002 2:45 PM-3:00 PM |
| Location: | Room 307A |
| Keywords: | DOPAMINE RECEPTOR, ACCUMBENS, FMRI, DRUG |
Functional magnetic resonance imaging (fMRI) was used in rats to study CNS effects of the dopamine D2/3 receptor agonist quinelorane in vivo. Male Sprague-Dawley rats (250-300g, n=5 per group) were anaesthetised (α-chloralose, 60mg/kg i.v. bolus, then 30mg/kg/hr) and scanned using multi-echo gradient echo imaging (TE=5,10 and 15ms, TR =460ms, 120 volumes in 2 hours). Quinelorane (30µg/kg, s.c.) or saline vehicle were randomly administered 30-60 minutes after scan initiation. Mean echo images were realigned, normalised to a rat-brain template and analysed using a general linear model[1]. Statistically significant signal intensity increases over controls (T>4.3, p<0.05) were detected within the nucleus accumbens, ventromedial striatum and olfactory nuclei. These results are consistent with previous microdialysis experiments where quinelorane, a potent D3 receptor agonist with high D3/D2 selectivity[2], reduced dopamine release in the nucleus accumbens and ventral striatum[3], areas rich in D3 receptors[2]. Our results provide further evidence that fMRI can be used in anaesthetised rats to characterise regional modulation of neural activity induced by psychotropic drugs. This non-invasive technique offers the possibility of longitudinal, within-subject studies in experimental animals that should result in novel neuropharmacological and pharmacokinetic findings with established and investigational new drugs. 1Lowe et al., 2001, Proc. ISMRM. 2Levant, 1997, Pharmacol. Rev., 49, 231-252. 3Thorn et al., 1997, Neuropharmacol., 36, 787-792.
Supported by GlaxoSmithKline
Research partly funded by GlaxoSmithKline Pharmaceuticals
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2002 Neuroscience Meeting Planner. Orlando, FL: Society for Neuroscience, 2002. Online.
Copyright © 2002-2025 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
